Insider Trading: Thomas E. Claugus’ GMT Capital Bought 85,400 Shares In $ENTG

Thomas E. Claugus’ GMT Capital today disclosed its recent insider purchases of 85,400 shares in Entegris Inc. (ENTG). GMT Capital made the purchases at $8.4 per share on December 19th. Now the firm takes 13.96 million in ENTG, which gives about 10.35% passive stake ownership. GMT Capital continuously bought ENTG in the fourth quarter. The firm reported 13.49 million shares on December 26th and 13.41 million shares at the end of September. ENTG is now trading at 8.55, up 14% in 2011.

Entegris Inc (NASDAQ:ENTG)

Ten hedge funds held ENTG in the third quarter. Beside GMT Capital, Richard Chilton’s Chilton Investment Company had 7.89 million shares. Cliff Asness’ AQR Capital Management took 956 thousand in the stock.

GMT Capital is a private investment company, targeting on long-term absolute returns in Basic Materials, Technology, Services, Financial, Consumer Goods and some other sectors. The company had a 13F portfolio of $4.4 billion in the second quarter. Mr. Thomas E. Claugus is the Founder and President at GMT Capital. Before he found the GMT Capital in 1990, he acted as a manager for Europe of the polymers division of Rohm and Haas.

Entegris, Inc. is a global developer, manufacturer and supplier. According to Google Finance, Entegris specializes in products and materials used in processing and manufacturing in the semiconductor and other high-technology industries. The company operates three segments: contamination control solutions segment, microenvironments segment, and its specialty materials segment. In October 2011, the company opened a new manufacturing and research facility in Hsinchu City, Taiwan. The company was founded in 1966 and is based in Billerica, Massachusetts.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!